TAP Partner News During AACR: April 10-15 2021
TAP Partner News During AACR: April 10-15 2021
AACR News and Information from Current and Former TAP Partners
Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of IRAKIMiD Degrader KT-413
WATERTOWN, Mass., April 10, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today presented late-breaking preclinical data showing how the dual targeting of IRAK4 and IMiD substrates by KT-413, its IRAKIMiD degrader currently in preclinical development, synergizes to impact signaling and cell killing in MYD88-mutant diffuse large B cell lymphoma (DLBCL) in a manner that is distinct from IMiDs or selective IRAK4 targeting alone.
Immune-Onc Therapeutics Announces Data for Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21
PALO ALTO, CA, April 10, 2021 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today the first public presentation of preclinical data for its first-in-class myeloid checkpoint inhibitor, IO-202, an LILRB4 antagonist antibody, in solid tumors. The electronic poster will be presented as part of the Immune Checkpoints Session of the American Association for Cancer Research (AACR) Annual Meeting 2021 (#AACR21), taking place virtually April 10-15, 2021.
Carisma Therapeutics Presents Data at The American Association for Cancer Research Annual Meeting
PHILADELPHIA, April 9, 2021 - CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15. The accepted data reinforces the potential of CARISMA's proprietary chimeric antigen receptor macrophage (CAR-M) platform, as well as the importance of evaluating CAR-monocytes (CAR-Mono) as a novel and expedited immunotherapeutic pathway.
Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
Heidelberg, Germany, April 9, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager (ICE®) AFM13 (CD16A/CD30).
Ryvu Therapeutics Presents Recent Data from Multiple Oncology Programs at AACR 2021
Krakow, Poland – March 11, 2021 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that its data from multiple oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21.